** Shares of Pennsylvania-based medtech firm Neuronetics STIM.O rise 8.2% to $4.61
** Company forecasts 2025 revenue between $145 million and $155 million, above analysts' estimate of $93.55 million, according to data compiled by LSEG
** Company, which offers its NeuroStar device to treat major depressive disorder (MDD), posts Q4 revenue of $22.49 million, beating analysts' estimates of $19.63 million
** In the last 12 months, STIM has fallen 41.5%
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。